Rachel Hu1, Allison Winter1, Brian T Hill2. 1. Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave - CA6, Cleveland, OH, 44195, USA. 2. Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave - CA6, Cleveland, OH, 44195, USA. hillb2@ccf.org.
Abstract
PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) is characterized by clinical heterogeneity that is not fully accounted for by pathologic features. Furthermore, real-time treatment modifications and detection of relapse are typically guided by radiographic imaging modalities which are imperfect. Here, we review the potential utility of minimal residual disease (MRD) assessment for informing treatment decisions and detecting relapse. RECENT FINDINGS: The most promising method of MRD detection is based on analysis of circulating tumor DNA in the peripheral blood of patients with DLBCL. This approach can predict outcomes and response to treatment as well as detect relapse prior to clinical signs of recurrent disease. While some studies of MRD in DLBCL have been in the prospective setting, the ability of this technology to alter clinical outcomes is currently unknown. MRD detection provides a non-invasive way to gather information about DLBCL at various time points throughout the disease course. Its role is evolving and should be incorporated into prospective studies in order to demonstrate an impact on patient outcomes.
PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) is characterized by clinical heterogeneity that is not fully accounted for by pathologic features. Furthermore, real-time treatment modifications and detection of relapse are typically guided by radiographic imaging modalities which are imperfect. Here, we review the potential utility of minimal residual disease (MRD) assessment for informing treatment decisions and detecting relapse. RECENT FINDINGS: The most promising method of MRD detection is based on analysis of circulating tumor DNA in the peripheral blood of patients with DLBCL. This approach can predict outcomes and response to treatment as well as detect relapse prior to clinical signs of recurrent disease. While some studies of MRD in DLBCL have been in the prospective setting, the ability of this technology to alter clinical outcomes is currently unknown. MRD detection provides a non-invasive way to gather information about DLBCL at various time points throughout the disease course. Its role is evolving and should be incorporated into prospective studies in order to demonstrate an impact on patient outcomes.
Entities:
Keywords:
Circulating tumor DNA; Diffuse large B cell lymphoma; Immunoglobulin next-generation sequencing; Minimal residual disease; Next generation sequencing
Authors: David W Scott; George W Wright; P Mickey Williams; Chih-Jian Lih; William Walsh; Elaine S Jaffe; Andreas Rosenwald; Elias Campo; Wing C Chan; Joseph M Connors; Erlend B Smeland; Anja Mottok; Rita M Braziel; German Ott; Jan Delabie; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Timothy C Greiner; Betty J Glinsmann-Gibson; Kai Fu; Louis M Staudt; Randy D Gascoyne; Lisa M Rimsza Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: Rachel E Lerner; William Thomas; Todd E Defor; Daniel J Weisdorf; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2007-02-15 Impact factor: 5.742
Authors: Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: Sebastian Böttcher; Matthias Ritgen; Sebastian Buske; Stefan Gesk; Wolfram Klapper; Eva Hoster; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling; Reiner Siebert; Michael Kneba; Christiane Pott Journal: Haematologica Date: 2008-04 Impact factor: 9.941
Authors: C Y Cheah; M S Hofman; M Dickinson; A Wirth; D Westerman; S J Harrison; K Burbury; M Wolf; H Januszewicz; K Herbert; H M Prince; D A Carney; D S Ritchie; R J Hicks; J F Seymour Journal: Br J Cancer Date: 2013-06-27 Impact factor: 7.640
Authors: Yeong Hak Bang; Joon Ho Shim; Kyung Ju Ryu; Yeon Jeong Kim; Myung Eun Choi; Sang Eun Yoon; Junhun Cho; Bon Park; Woong-Yang Park; Won Seog Kim; Seok Jin Kim Journal: J Cancer Date: 2022-02-21 Impact factor: 4.207